Archives

  • 2019-10
  • 2019-11
  • 2020-03
  • 2020-07
  • 2020-08
  • 50-07-7 br Con iframe width height src https

    2020-08-30


    4. Conclusion
    As shown in this Review Article, Cathepsins could be very efficient tools, leverages or even actuators for the design of advanced drug de-livery systems. It has been shown that these systems were sensitive to the presence of a broad spectrum of different Cathepsins, leading to enhanced therapeutic benefit and imaging capabilities. Among the nu-merous Cathepsin-sensitive conjugates reported so far, some of them have shown promising results and even reached advanced clinical tri-als. However, a great deal of work remains especially regarding the lack of site specificity and the still limited understanding of the biolog-ical roles of some proteases. These limitations must be resolved to de-velop optimized conjugates and offer more prominent clinical candidates.
    Also, it 50-07-7 has been demonstrated that cysteine Cathepsin proteases can act as regulators for cancer progression as well as therapeutic response [232]. It means that they can either promote tumor growth or suppress tumor depending upon the environment. However, more clinical inves-tigations must be performed to have a complete and accurate picture of the situation in vivo.
    Conflict of interest
    The authors confirm that there are no known conflicts of interest as-sociated with the content of this article.
    Acknowledgement
    D.D. thank to Indo French Centre for Promotion of Advanced Re-search (IFCPAR/CEFIPRA) for Raman Charpak Fellowship 2017 and CSIR-New Delhi, India for her research fellowship. This research work was financially supported by DST EMR/2016/002304 and DST EEQ/ 2016/000102 and IIIM communication no. IIIM/2244/2018. CNRS and Université Paris-Sud are also acknowledged for financial support.
    References
    [6] D. Brömme, S. Wilson, Role of cysteine Cathepsins in extracellular proteolysis, in: R.P. Mecham Parks (Ed.), W.C, Extracellular Matrix Degradation, Springer Berlin Heidelberg, Berlin, Heidelberg 2011, pp. 23–51.
    [7] K. Oikonomopoulou, E.P. Diamandis, M.D. Hollenberg, V. Chandran, Proteinases and their receptors in inflammatory arthritis: an overview, Nat. Rev. Rheumatol. 14 (2018) 170.
    [27] S. Ferber, H. Baabur-Cohen, R. Blau, Y. Epshtein, E. Kisin-Finfer, O. Redy, D. Shabat, R. Satchi-Fainaro, Polymeric nanotheranostics for real-time non-invasive optical imaging of breast cancer progression and drug release, Cancer Lett. 352 (2014) 81–89.
    [28] J. Nicolas, S. Mura, D. Brambilla, N. Mackiewicz, P. Couvreur, Design, functionalization strategies and biomedical applications of targeted biodegrad-able/biocompatible polymer-based nanocarriers for drug delivery, Chem. Soc. Rev. 42 (2013) 1147–1235.
    Please cite this article as: D. Dheer, J. Nicolas and R. Shankar, Cathepsin-sensitive nanoscale drug delivery systems for cancer therapy and other diseases, Adv. Drug Deliv. Rev., https://doi.org/10.1016/j.addr.2019.01.010
    [52] H. Hentze, X.Y. Lin, M.S.K. Choi, A.G. Porter, Critical role for cathepsin B in mediat-ing caspase-1-dependent interleukin-18 maturation and caspase-1-independent necrosis triggered by the microbial toxin nigericin, Cell Death Differ. 10 (2003) 956–968.
    [53] D. Cavallo-Medved, J. Mai, J. Dosescu, M. Sameni, B.F. Sloane, Caveolin-1 mediates the expression and localization of cathepsin B, pro-urokinase plasminogen activa-tor and their cell-surface receptors in human colorectal carcinoma cells, J. Cell Sci. 118 (2005) 1493–1503.
    M. Hugh, O.S. Jacintha, Localization of nuclear cathepsin L and its association with disease progression and poor outcome in colorectal cancer, Int. J. Cancer 125 (2009) 54–61. [66] M. Konno-Shimizu, N. Yamamichi, K.-i. Inada, N. Kageyama-Yahara, K. Shiogama, Y. Takahashi, I. Asada-Hirayama, M. Yamamichi-Nishina, C. Nakayama, S. Ono, S. Kodashima, M. Fujishiro, Y. Tsutsumi, M. Ichinose, K. Koike, Cathepsin E is a marker of gastric differentiation and signet-ring cell carcinoma of stomach: A novel sug-gestion on gastric tumorigenesis, PLoS One 8 (2013) e56766.
    [72] D. Dian, T. Vrekoussis, N. Shabani, I. Mylonas, C. Kuhn, C. Schindlbeck, I. Navrozoglou, K. Friese, A. Makrigiannakis, U. Jeschke, Expression of cathepsin-D in primary breast cancer and corresponding local recurrence or metastasis: an im-munohistochemical study, Anticancer Res. 32 (2012) 901–905.
    T. Itinteang, Expression and localization of cathepsins B, D and G in cancer stem cells in liver metastasis from colon adenocarcinoma, Front. Surg. 5 (2018) 40.
    [74] M.Z.I. Pranjol, N.J. Gutowski, M. Hannemann, J.L. Whatmore, Cathepsin D non-proteolytically induces proliferation and migration in human omental microvascu-lar endothelial cells via activation of the ERK1/2 and PI3K/AKT pathways, Biochim. Biophys. Acta, Mol. 50-07-7 Cell Res. 1865 (2018) 25–33.